Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy

Chinese Medical Journal

Volumn 126, Issue 22, 2013, Pages 4395-4396

  Jiao, Xiu Min ^a   Jiao, Xiu Juan ^b   Zhang, Xing Guang ^a   Xu, Xiu Ping ^a   Wu, Jin Xiao ^a   Yao, Lu ^a   Zhao, Jing ^a   Lü, Xiao Feng ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Department of Gastroenterology   (China)

Author keywords

Cilostazol; Diabetic nephropathy; Urinary albumin

Indexed keywords

ALANINE AMINOTRANSFERASE; CELL ADHESION MOLECULE; CILOSTAZOL; HEMOGLOBIN A1C; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO;

BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; FEMALE; HUMAN; MALE; MICROALBUMINURIA; NOTE;

ALBUMINURIA; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; TETRAZOLES;

EID: 84887581121     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20131503     Document Type: Note

References (4)

1. Tang FR. The prevalence rate and risk factors of diabetic nephropathy in type 2 diabetes. China J Mod Med (Chin) 2005; 15: 152-152.
2. Li JM, Shah AM. ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J Am Soc Nephm1 2003; 14 (8 Suppl 3): S221.
3. Ha H, Lee HB. Reactive oxygen species and matrix remodeling in diabetic kidney. J Am Soc Nephro1 2003; 14 (8 Suppl 3): S246
4. Thomson SC, Vallon V, Blantz RC. Kidney function in early diabetes: The tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol 2004; 286: F8-F15.